Literature DB >> 19534622

The cytological, clinical, and pathological features of the cribriform-morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes.

Chan-Kwon Jung1, Yeong-Jin Choi, Kyo-Young Lee, Ja-Seong Bae, Hyung-Jin Kim, Seung-Kew Yoon, Young-Ik Son, Jae Hoon Chung, Young Lyun Oh.   

Abstract

BACKGROUND: The cribriform-morular variant of papillary thyroid carcinoma (CMVPTC) is an unusual subtype of papillary thyroid carcinoma. The goal of this study was to determine the clinicopathological features of CMVPTC and whether the tumor can be diagnosed by fine-needle aspiration cytology.
METHODS: We retrospectively analyzed the clinical appearance and pathological findings in five patients with CMVPTC and sequenced exon 3 of CTNNB1 and exon 15 of BRAF in tumor tissue.
RESULTS: All patients were young women, 15-34 years of age at the time of the cancer diagnosis. Preoperative cytological examination showed scattered tall columnar cells, fascicular spindle cells, and cribriform and morular patterns in the fine-needle aspirates of the thyroid from the five patients. Grossly, all tumors were well-circumscribed, solid or cystic. Immunohistochemically, most tumor cells showed nuclear expression of thyroid transcription factor-1, estrogen and progesterone receptors, and p53; cytoplasmic expression of cytokeratins 7 and 19, vimentin, and bcl-2; and cytoplasmic and nuclear accumulation of beta-catenin and galectin-3. There was no expression of thyroglobulin, cytokeratin 5/6, or human mesothelial cell-1. However, among these markers, the morular cells showed only positive immunostaining for beta-catenin, galectin-3, p53, and bcl-2. A CTNNB1 mutation was identified in only one case and no BRAF mutation was found in any of the five cases.
CONCLUSIONS: Taken together, these data suggest that CMVPTC can be diagnosed preoperatively, based on careful cytology examination, and shows unique immunohistochemical findings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19534622     DOI: 10.1089/thy.2008.0332

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  12 in total

Review 1.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

2.  Cribriform morular variant of papillary thyroid carcinoma: Cytomorphology, differential diagnosis and diagnostic implications in patients with adenomatous polyposis coli.

Authors:  Amarathunga Ah Priyani; Shamika T Opatha; Nisayuri W Gunathilake; Menaka Ds Lokuhetty
Journal:  J Cytol       Date:  2016 Oct-Dec       Impact factor: 1.000

3.  Prediction of cervical lymph node metastasis with contrast-enhanced ultrasound and association between presence of BRAFV600E and extrathyroidal extension in papillary thyroid carcinoma.

Authors:  Jia Zhan; Long-Hui Zhang; Qing Yu; Chao-Lun Li; Yue Chen; Wen-Ping Wang; Hong Ding
Journal:  Ther Adv Med Oncol       Date:  2020-08-06       Impact factor: 8.168

4.  TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma.

Authors:  Eun Ji Oh; Sohee Lee; Ja Seong Bae; Yourha Kim; Sora Jeon; Chan Kwon Jung
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

5.  LEF-1 is a Sensitive Marker of Cribriform Morular Variant of Papillary Thyroid Carcinoma.

Authors:  Shalini Mohindra; Hany Sakr; Charles Sturgis; Deborah J Chute
Journal:  Head Neck Pathol       Date:  2017-12-14

6.  BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma.

Authors:  Dagmara Rusinek; Michal Swierniak; Ewa Chmielik; Monika Kowal; Malgorzata Kowalska; Renata Cyplinska; Agnieszka Czarniecka; Wojciech Piglowski; Joanna Korfanty; Mykola Chekan; Jolanta Krajewska; Sylwia Szpak-Ulczok; Michal Jarzab; Wieslawa Widlak; Barbara Jarzab
Journal:  PLoS One       Date:  2015-12-01       Impact factor: 3.240

Review 7.  A unique case of two somatic APC mutations in an early onset cribriform-morular variant of papillary thyroid carcinoma and overview of the literature.

Authors:  M D Aydemirli; K van der Tuin; F J Hes; A M W van den Ouweland; T van Wezel; E Kapiteijn; H Morreau
Journal:  Fam Cancer       Date:  2020-01       Impact factor: 2.375

8.  Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population.

Authors:  Hye Sook Min; Chul Lee; Kyeong Cheon Jung
Journal:  J Korean Med Sci       Date:  2013-03-27       Impact factor: 2.153

9.  Classic papillary thyroid carcinoma with tall cell features and tall cell variant have similar clinicopathologic features.

Authors:  Woo Jin Oh; Young Sub Lee; Uiju Cho; Ja Seong Bae; Sohee Lee; Min Hee Kim; Dong Jun Lim; Gyeong Sin Park; Youn Soo Lee; Chan Kwon Jung
Journal:  Korean J Pathol       Date:  2014-06-26

10.  Identification of Biomarkers Based on Differentially Expressed Genes in Papillary Thyroid Carcinoma.

Authors:  Jun Han; Meijun Chen; Yihan Wang; Boxuan Gong; Tianwei Zhuang; Lingyu Liang; Hong Qiao
Journal:  Sci Rep       Date:  2018-07-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.